Alexandra Kazanova
Overview
Explore the profile of Alexandra Kazanova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tu T, Grunbaum A, Santinon F, Kazanova A, Rozza N, Kremer R, et al.
Commun Biol
. 2024 May;
7(1):526.
PMID: 38702425
COVID-19, caused by SARS-CoV-2, can lead to a severe inflammatory disease characterized by significant lymphopenia. However, the underlying cause for the depletion of T-cells in COVID-19 patients remains incompletely understood....
2.
Zyryanov S, Bondareva I, Butranova O, Kazanova A
Front Pharmacol
. 2023 Apr;
14:1079680.
PMID: 37007022
Preterm neonates rarely participate in clinical trials, this leads to lack of adequate information on pharmacokinetics for most drugs in this population. Meropenem is used in neonates to treat severe...
3.
Guo X, Kazanova A, Thurmond S, Saragovi H, Rudd C
iScience
. 2021 Oct;
24(11):103295.
PMID: 34693218
Current therapies to treat coronavirus disease 2019 (COVID-19) involve vaccines against the spike protein S1 of SARS-CoV-2. Here, we outline an alternative approach involving chimeric antigen receptors (CARs) in T ...
4.
Krueger J, Santinon F, Kazanova A, Issa M, Larrivee B, Kremer R, et al.
PLoS One
. 2021 Jun;
16(6):e0251731.
PMID: 34181666
Immunotherapy using checkpoint blockade (ICB) with antibodies such as anti-PD-1 has revolutionised the treatment of many cancers. Despite its use to treat COVID-19 patients and autoimmune diseases such as systemic...
5.
Kazanova A, Rudd C
PLoS Biol
. 2021 May;
19(5):e3001272.
PMID: 34010274
A recent study shows that programmed cell death 1 ligand (PD-L1) on activated T cells promotes their conversion to suppressive inducible regulatory T cells (iTregs), preferentially from among memory T...